In Vivo Evaluation of the Acute Systemic Toxicity of (1S,2E,4R,6R,7E,11E)-Cembratriene-4,6-diol (4R) in Sprague Dawley Rats

The tobacco cembranoid (1S,2E,4R,6R,7E,11E)-2,7,11-cembratriene-4,6-diol (4R) interacts with nicotinic acetylcholine receptors, which results in neuroprotection against organophosphate toxicity, brain ischemia, and Parkinson’s disease. The present study is a continuation of our previous research in...

Full description

Saved in:
Bibliographic Details
Published inNutraceuticals Vol. 2; no. 2; pp. 60 - 70
Main Authors Sabeva, Nadezhda, Pagán, Oné R., Ferrer-Acosta, Yancy, Eterović, Vesna A., Ferchmin, Peter A.
Format Journal Article
LanguageEnglish
Published 09.04.2022
Online AccessGet full text

Cover

Loading…
More Information
Summary:The tobacco cembranoid (1S,2E,4R,6R,7E,11E)-2,7,11-cembratriene-4,6-diol (4R) interacts with nicotinic acetylcholine receptors, which results in neuroprotection against organophosphate toxicity, brain ischemia, and Parkinson’s disease. The present study is a continuation of our previous research in which we applied a single dose of 4R 1 h before or 24 h after exposure to diisopropylfluorophosphate (DFP) (analog of the nerve agent sarin). The 4R dose robustly decreased neuroinflammation and neuronal death at both timepoints. Here, we investigated the toxicity of a single dose of 4R in male and female Sprague Dawley (SD) rats after a subcutaneous (s.c.) injection of 6, 24, or 98 mg/kg. Body weight was not affected by 4R during the 7-day observation period. No histopathologic changes in the organs were attributed to 4R. Minor hematological and blood composition variations were detected on Day 3 in the mid- and the high-dose males, but these were resolved by Day 8. At the area of the s.c. injection site, alopecia and dry skin were detected in both the 4R-treated males and females and in the female controls.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author Contributions: Conceptualization, P.A.F., N.S., O.R.P. and V.A.E.; methodology, P.A.F. and N.S.; validation, N.S.; formal analysis, P.A.F., N.S. and O.R.P.; investigation, P.A.F., N.S., O.R.P. and V.A.E.; data curation, N.S. and O.R.P.; writing—original draft preparation, P.A.F., N.S. and O.R.P.; writing—review and editing, Y.F.-A.; visualization, N.S.; supervision, N.S. and P.A.F.; project administration, P.A.F. and N.S.; funding acquisition, P.A.F. and N.S. All authors have read and agreed to the published version of the manuscript.
ISSN:1661-3821
1661-3821
DOI:10.3390/nutraceuticals2020005